A Study to Test if Fremanezumab is Effective in Preventing Episodic Migraine in Patients 6 to 17 Years of Age

PHASE3CompletedINTERVENTIONAL
Enrollment

235

Participants

Timeline

Start Date

July 15, 2020

Primary Completion Date

March 13, 2024

Study Completion Date

March 13, 2024

Conditions
Migraine
Interventions
DRUG

Fremanezumab

Dose A or Dose B subcutaneous

DRUG

Placebo

Matching placebo

Trial Locations (89)

13353

Teva Investigational Site 32729, Berlin

14226

Teva Investigational Site 14276, Amherst

20132

Teva Investigational Site 30239, Milan

20133

Teva Investigational Site 30228, Milan

20148

Teva Investigational Site 30226, Milan

21201

Teva Investigational Site 14365, Baltimore

23510

Teva Investigational Site 14323, Norfolk

26505

Teva Investigational Site 14317, Silver Spring

27100

Teva Investigational Site 30227, Pavia

27607

Teva Investigational Site 14248, Raleigh

27710

Teva Investigational Site 14377, Durham

28007

Teva Investigational Site 31268, Madrid

28046

Teva Investigational Site 31267, Madrid

30328

Teva Investigational Site 14243, Atlanta

31406

Teva Investigational Site 14258, Savannah

32256

Teva Investigational Site 14244, Jacksonville

33155

Teva Investigational Site 14325, Miami

33407

Teva Investigational Site 14250, West Palm Beach

33409

Teva Investigational Site 14255, West Palm Beach

33521

Teva Investigational Site 40052, Tampere

35128

Teva Investigational Site 30238, Padua

37620

Teva Investigational Site 14374, Bristol

39157

Teva Investigational Site 14376, Ridgeland

40202

Teva Investigational Site 14327, Louisville

45133

Teva Investigational Site 32724, Essen

46026

Teva Investigational Site 31270, Valencia

47010

Teva Investigational Site 31265, Valladolid

48104

Teva Investigational Site 14251, Ann Arbor

50139

Teva Investigational Site 30230, Florence

55402

Teva Investigational Site 14270, Minneapolis

58100

Teva Investigational Site 80168, Holon

60068

Teva Investigational Site 14283, Park Ridge

60169

Teva Investigational Site 14263, Hoffman Estates

61350

Teva Investigational Site 32728, Bad Homburg

67206

Teva Investigational Site 14245, Wichita

70210

Teva Investigational Site 40049, Kuopio

70433

Teva Investigational Site 14360, Covington

72202

Teva Investigational Site 14281, Little Rock

73112

Teva Investigational Site 14257, Oklahoma City

73116

Teva Investigational Site 14275, Oklahoma City

74136

Teva Investigational Site 14363, Tulsa

77087

Teva Investigational Site 14312, Houston

77401

Teva Investigational Site 14274, Bellaire

78207

Teva Investigational Site 14366, San Antonio

78240

Teva Investigational Site 14241, San Antonio

78731

Teva Investigational Site 14252, Austin

78759

Teva Investigational Site 14273, Austin

80045

Teva Investigational Site 14319, Aurora

80907

Teva Investigational Site 14368, Colorado Springs

84109

Teva Investigational Site 14375, Salt Lake City

90027

Teva Investigational Site 14322, Los Angeles

90100

Teva Investigational Site 40054, Oulu

92220

Teva Investigational Site 14253, Banning

92354

Teva Investigational Site 14370, Loma Linda

95815

Teva Investigational Site 14361, Sacramento

98405

Teva Investigational Site 14277, Tacoma

1311001

Teva Investigational Site 80164, Safed

3339419

Teva Investigational Site 80166, Haifa

5265601

Teva Investigational Site 80167, Ramat Gan

6423906

Teva Investigational Site 80165, Tel Aviv

7033001

Teva Investigational Site 80170, Be’er Ya‘aqov

9124001

Teva Investigational Site 80169, Jerusalem

02451

Teva Investigational Site 14246, Waltham

63044-2513

Teva Investigational Site 14256, Bridgeton

08901

Teva Investigational Site 14371, New Brunswick

45229-3039

Teva Investigational Site 14264, Cincinnati

19104-4318

Teva Investigational Site 14364, Philadelphia

75235-7701

Teva Investigational Site 14367, Dallas

L1Z 0M1

Teva Investigational Site 11180, Ajax

K1H 8L1

Teva Investigational Site 11182, Ottawa

K2G 1W2

Teva Investigational Site 11179, Ottawa

H4A 3J1

Teva Investigational Site 11181, Montreal

00380

Teva Investigational Site 40053, Helsinki

01307

Teva Investigational Site 32725, Dresden

04177

Teva Investigational Site 32726, Leipzig

00163

Teva Investigational Site 30225, Rome

7009 BL

Teva Investigational Site 38138, Doetinchem

6532 SZ

Teva Investigational Site 38135, Nijmegen

3015 GD

Teva Investigational Site 38136, Rotterdam

80-389

Teva Investigational Site 53441, Gdansk

25-316

Teva Investigational Site 53437, Kielce

30-363

Teva Investigational Site 53443, Krakow

30-539

Teva Investigational Site 53452, Krakow

20-582

Teva Investigational Site 53440, Lublin

60-355

Teva Investigational Site 53439, Poznan

61-731

Teva Investigational Site 53451, Poznan

70-111

Teva Investigational Site 53442, Szczecin

08035

Teva Investigational Site 31271, Barcelona

03600

Teva Investigational Site 31266, Elda

All Listed Sponsors
lead

Teva Branded Pharmaceutical Products R&D, Inc.

INDUSTRY

NCT04458857 - A Study to Test if Fremanezumab is Effective in Preventing Episodic Migraine in Patients 6 to 17 Years of Age | Biotech Hunter | Biotech Hunter